MAPT and type 2 diabetes mellitus: In context, empagliflozin was reported to reduce Aβ, Tau phosphorylation and brain atrophy along with improving learning and memory in a mixed mice model of AD and diabetes type 2 (Hierro-Bujalance et al. 2020).